Morgan Stanley
BIOA

Morgan Stanley’s BioAge Labs BIOA Stock Holding History

Morgan Stanley’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Buy
282,386
+22,517
+9% +$407K ﹤0.01% 4005
2026
Q1 		$4.55M Sell
259,869
-51,790
-17% -$997K ﹤0.01% 4210
2025
Q4 		$4.12M Buy
311,659
+83,501
+37% +$740K ﹤0.01% 4328
2025
Q3 		$1.34M Buy
228,158
+14,655
+7% +$68.6K ﹤0.01% 5009
2025
Q2 		$882K Buy
213,503
+183,877
+621% +$741K ﹤0.01% 5168
2025
Q1 		$111K Sell
29,626
-413,327
-93% -$1.91M ﹤0.01% 5957
2024
Q4 		$2.56M Buy
442,953
+440,644
+19,084% +$7.6M ﹤0.01% 4532
2024
Q3 		$48K Buy
+2,309
New +$46.3K ﹤0.01% 6231

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Morgan Stanley's BIOA Position: Q2 2026 in Review

Morgan Stanley increased its BioAge Labs (BIOA) stake by 8.7% in Q2 2026, buying an estimated $407K and bringing the position to 282,386 shares worth $6.92M. The position accounts for ﹤0.01% of the portfolio, ranked #4005.

Morgan Stanley first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Morgan Stanley held 282,386 shares of BioAge Labs worth $6.92M as of Q2 2026.
  • Morgan Stanley bought 22,517 BioAge Labs shares in Q2 2026, an estimated $407K.
  • BioAge Labs made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4005 holding.
  • Morgan Stanley first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.